Şirket yükleniyor
Labcorp Holdings Inc.
LH · NYSE · ·
$370,57-%0,513 Kas kapanış
30 Eylül 2026 tarihine kadarki rakamlar, 30 Ekim 2026 tarihinde sunulan 10-Q raporundan
Geçmiş getiri
- 1W
- +%1,1
- 1M
- +%16,8
LH · NYSE · ·
$370,57-%0,513 Kas kapanış
30 Eylül 2026 tarihine kadarki rakamlar, 30 Ekim 2026 tarihinde sunulan 10-Q raporundan
Just reported
From Labcorp's results release of 28 Ekim 2026; its quarterly report has since been filed.
Actual
$3,81B
+%6,9 y/y
+%2,1 q/q
Guided
—
No guide given
Actual
$3,22
+%3,2 y/y
-%12 q/q
Guided
—
No guide given
Actual
$402,1M
+%1,4 y/y
-%11 q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Gelir payları year ended 2025-12-31 dönemi için tahmindir; resmî bir bildirimden alınmış rakamlar değildir.
Routine and specialty diagnostic tests
Laboratory tests on patient samples, including tests used to diagnose and monitor diseases, as well as occupational, wellness and forensic deoxyribonucleic acid (DNA) testing.
ColoSense
A stool-based colorectal cancer screening test that people collect at home; it is approved by the U.S. Food and Drug Administration (FDA).
PlasmaDetect genome minimal residual disease (MRD)
A blood test being evaluated for monitoring whether early-stage lung cancer returns after treatment.
Labcorp OnDemand
A service through which consumers can order certain health and wellness tests directly, including tests for cancer screening, allergies and men's and women's health.
Central laboratory services
Laboratory testing for pharmaceutical and biotechnology companies conducting clinical studies of medicines.
Early development laboratory services
Laboratory services supporting early stages of drug research and development.
Labcorp tests patient samples at its laboratories, performing routine and specialty tests for diagnosing and monitoring health conditions. Its Biopharma Laboratory Services business performs laboratory work for pharmaceutical, biotechnology, medical device and diagnostic companies, including central laboratory testing and early development services. Patients can also order some tests directly through Labcorp OnDemand.
Labcorp Holdings Inc. şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.
The themes Labcorp is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Labcorp sells medical testing to doctors, hospitals, health plans and patients, plus drug-development laboratory testing to pharmaceutical and biotechnology companies.
Grade A
Fiyatın altındaki şerit, her tarihteki notu gösterir; yalnızca o tarihe kadar yayımlanmış belgelerden hesaplanır.
Labcorp Holdings Inc. şirketinin not geçmişinin 41 çeyreğinden 2 tanesi gösteriliyor. Diğer 39 çeyrek Ekim 2016 tarihine kadar uzanıyor.
